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Abstract
Case reports of Burkitt lymphoma (BL) in transplant recipients suggest that the risk is markedly
elevated. Therefore, we investigated the incidence of BL in 203,557 solid organ recipients in the
U.S. Transplant Cancer Match Study (1987–2009) and compared it to the general population using
standardized incidence ratios (SIRs). We also assessed associations with demographic and clinical
characteristics, and treatments used to induce therapeutic immunosuppression. BL incidence was
10.8 per 100,000 person-years, representing 23-fold (95%CI 19–28) greater risk than in the
general population, and it peaked 3–8 years after the time of transplantation. In adjusted analyses,
BL incidence was higher in recipients transplanted when <18 vs. ≥35 years (incidence rate ratio
[IRR] 3.49, 95% CI 2.08–5.68) and in those transplanted with a liver (IRR 2.91, 95% CI 1.68–
5.09) or heart (IRR 2.39, 95% CI 1.30–4.31) compared to kidney. BL incidence was lower in
females than males (IRR 0.45, 95% CI 0.28–0.71), in blacks than whites (IRR 0.33, 95% CI 0.12–
0.74), in those with a baseline Epstein-Barr virus (EBV)-seropositive versus EBV-seronegative
status (IRR 0.34, 95% CI 0.13–0.93), and in those treated with azathioprine (IRR 0.56, 95% CI
0.34–0.89) or corticosteroids (IRR 0.48, 95% CI 0.29–0.82). Tumors were EBV-positive in 69%
of 32 cases with results. EBV positivity was 90% in those aged <18 years and 59% in those aged
18+ years. In conclusion, BL risk is markedly elevated in transplant recipients, and it is associated
with certain demographic and clinical features. EBV infection was present in most but not all BL
cases.
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Introduction
Burkitt lymphoma (BL) is an aggressive B-cell non-Hodgkin lymphoma (NHL) that is
endemic in parts of Africa and New Guinea, [1] and occurs sporadically in Europe and
North America.[2] Although endemic and sporadic BL are recognized by the World Health
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organization as distinct entities, [2] they are histologically indistinguishable and share in
common translocation of the c-MYC proto-oncogene on chromosome 8 (8q24) near the
sequences that regulate heavy or light chain immunoglobulin genes on chromosomes 14q32,
2p12, or 22q11. [3, 4] Endemic BL is linked to Epstein-Barr virus (EBV) and Plasmodium
falciparum malaria infections,[5–7] but the etiology of sporadic BL has not been identified.
BL also occurs in association with immunosuppression in persons with human
immunodeficiency virus (HIV) infection and in solid organ transplant recipients,[8] and
EBV infection is thought to be the main driver of BL in immunosuppressed persons. [9] The
risk of BL is increased 60-fold among persons with HIV as compared to the general
population. [10]
Case reports of BL in transplant recipients are consistent with an elevated risk for BL,[11–
13] but the incidence of BL and its risk factors have not been described. Use of solid organ
transplantation has grown steadily over the past 20–30 years.[14] With improved transplant
outcomes, cancer is becoming an increasing problem for transplant recipients. To gain
insights into BL and obtain valuable data for clinicians and public health workers, we
investigated the incidence and risk factors for BL among solid organ transplant recipients in
the U.S. using data from the Transplant Cancer Match (TCM) Study for the period 1987–
2009.
Methods
The U.S. TCM Study (http://transplantmatch.cancer.gov/) utilizes linked data from the
Scientific Registry of Transplant Recipients (SRTR) and population-based cancer registries
in 15 states and/or metropolitan areas. [15] The SRTR data come from the Organ
Procurement and Tissue Network (OPTN), which coordinates transplantation in the U.S. All
U.S. transplant centers routinely provide OPTN with recipient demographic, baseline
clinical, 6-month post-transplant and annual follow-up data. Only transplant recipients
residing in the areas with cancer registries used in the linkage were included. Population-
based cancer registry data were obtained from California (1988–2008), Colorado (1988–
2006), Connecticut (1973–2006), Florida (1981–2009), Georgia (1995–2008), Hawaii
(1973–2007), Illinois (1986–2007), Iowa (1973–2009), Michigan (1985–2006), North
Carolina (1990–2007), New Jersey (1979–2006), New York (1976–2007), the Seattle-Puget
Sound area of Washington State (1974–2008), Texas (1995–2006), and Utah (1973–2008).
Institutional review boards at participating sites and at the National Cancer Institute gave
approval to conduct the study.
Statistical analysis
BL cases were identified from cancer registry data using morphology codes provided by the
cancer registries. The morphology codes for BL used during the study period include 9750/3
in the International Classification of Diseases for Oncology (ICD-O) published in 1976 [16]
for the cases registered from 1987–1991 and codes 9687/3 and 9826/3 in ICD-O-2 and ICD-
O-3 published in 1990[17] and 2000 [18], respectively, for the cases registered from 1992–
2009. The cancer registries re-coded the BL cases from the early period to ICD-O-3 9687/3
and 9826/3 morphology codes, [18] which were used in the current study. BL incidence in
recipients was expressed as the number of cases per 100,000 person-years of follow-up.
Each transplant was considered as a separate period at risk. Person-time was calculated from
the time of transplantation or start of cancer registry coverage (whichever occurred later)
until BL diagnosis, failure of a transplanted organ, re-transplant, death, last follow-up date,
or end of cancer registry coverage (whichever occurred earliest).
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Standardized incidence ratios (SIRs) were used to estimate the fold-increase in BL incidence
relative to the general population. SIRs were calculated as the number of observed BL cases
in the transplant recipients divided by the number of expected BL cases. The expected
number of BL cases was calculated using general population rates applied to the person-time
at risk in transplant recipients. These calculations were performed in strata defined by age-,
race-, sex-, calendar year, and registry region and then summed to get the total expected
count. Exact 95% confidence intervals (95% CIs) of the SIRs were derived.
We assessed potential BL risk factors, such as clinical and treatment characteristics, using
incidence rate ratios (IRRs) calculated in univariate Poisson regression models. Sex, age at
transplantation, transplanted organ, time since transplantation, race, and baseline EBV
serostatus were considered a priori to be potentially important risk factors for BL, so these
variables were used to construct a base multivariate model that was utilized to assess
independent contribution of other covariates identified in univariate models. Calendar year
of transplantation was collinear with time since transplantation, so it was not included in
multivariate models. The likelihood ratio test was used to determine whether each variable
was significantly associated with BL in the multivariable model. A two-sided P value of
<0.05 was considered statistically significant.
We performed secondary analyses to gain insights into EBV patterns in BL tumors. BL is
one type of post-transplant lymphoproliferative disease (PTLD), and some BL cases had
PTLD reported to the SRTR by their transplant center. After comparing the similarity of the
dates of diagnosis of the PTLD record to the date of BL recorded in the cancer registry, we
concluded that a diagnosis coded as PTLD in the SRTR and as BL in the cancer registry
were both referring to the same tumor episode in the recipient. Therefore, we utilized the
EBV results on PTLD cases in the SRTR to infer EBV status in the tumor for the linked BL
cases.
Results
We studied 203,557 transplant recipients, of whom 61% were male and 62% were non-
Hispanic whites, 17% blacks and 16% Hispanics (Table I). The three most commonly
transplanted organs were kidney (58%), liver (22%), and a thoracic organ (heart and/or lung,
14%). Baseline EBV serostatus was known for 34% of the recipients, among whom 83%
were seropositive. Among recipients with known EBV serostatus, seropositivity did not
differ by race (range was 83–84%). Baseline HIV infection status was known for 37% of the
recipients, and HIV infection was rare (0.3%).
BL was identified in 99 recipients, and the median age at BL was 47 years. Males comprised
76% of the cases, and by race, 69% were non-Hispanic whites, 23% Hispanics, 5% blacks
and 3% Asian/Pacific Islanders (Table II). The distribution of age at the time of
transplantation of the BL cases was 28%, 17%, 23%, 27% and 4% for ages 0–19, 20–34,
35–49, 50–64, and 65+ years, respectively (Table II).
The anatomic site of BL was recorded as lymph nodes in 75% of the cases, and was
distributed as follows: 14% in cervical, axilla region, or intra-thoracic nodes, 11% in
abdominal or pelvic nodes, 32% in multiple nodal sites, and 18% in unspecified nodal sites.
The anatomic sites were extranodal in 25% of the cases, and distributed as follows: 16%
abdominal, including the small or large intestine and liver, 4% in bone marrow, and 5% in
miscellaneous sites including the nasopharynx, mediastinum, spinal cord/meninges, and soft
tissue.
A PTLD record was found in the SRTR for 53 (54%) of the 99 BL cases. The mean time
from the BL diagnosis date to the PTLD diagnosis date was 0.1 month (range −9 months to
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+13 months). EBV was positive in 69% (22 of 32 cases) and negative in 31% (10 of 32), and
unknown in 21 cases. BL was EBV positive in 90% of 10 cases age 0–17 years at BL
diagnosis, 58% of 12 cases age 18–49 years, and 60% of 10 cases age 50+ years. The 22
EBV-positive PTLD/BL cases were diagnosed in four recipients who were EBV-
seronegative at baseline, 4 who were EBV-seropositive, and 14 whose EBV serostatus was
unknown. The 10 EBV-negative PTLD/BL cases were diagnosed in three recipients who
were EBV seropositive at baseline and in seven recipients whose EBV baseline status was
unknown.
The BL incidence rate in transplant recipients was 10.8 per 100,000 person-years. The
incidence was low in the first two years after transplantation, but rose steeply in the third
year and remained elevated for 3–8 years after transplantation (Figure 1). BL incidence was
23-fold (95%CI 19–28) greater in transplant recipients than in the general population. The
incidence was 410-fold (95% CI 10–2300) higher in HIV-infected recipients than in the
general population, but this result was based on only one HIV-infected case and thereby risk
estimation is unstable. Among recipients, BL incidence in females was half that observed
among males (P<0.001; Table II). BL incidence was also inversely related to age at
transplantation (Ptrend <0.001). BL incidence among blacks was a third of that observed
among whites (P=0.015), but the rate among Hispanics and Asians/Pacific Islanders was
similar to that in whites. The incidence of BL among blacks compared to whites remained
significantly decreased in analyses adjusting for baseline EBV serostatus (adjusted IRR
0.33, 95% CI 0.12–0.74; Table II).
BL incidence was 3–3.5 times higher in those recipients transplanted with a liver or heart
than in those transplanted with a kidney (P<0.001) (Table III). BL incidence in recipients
with baseline EBV seropositive status was only one-fourth of the incidence in those with
EBV seronegative status (IRR 0.24, P=0.003). A similar pattern was observed for baseline
cytomegalovirus serostatus (IRR 0.4, P=0.025), based on 49% of subjects with
cytomegalovirus serostatus, but the association was not independent of baseline EBV
serostatus (data not shown). BL incidence was not significantly related to a history of
diabetes mellitus (Table III) or another 23 specific medical conditions listed as the indication
for transplant (see Supplemental Tables I-IV). The possible exception was a decreased BL
incidence for non-cholestatic cirrhosis and an increased incidence with cholestatic liver
disease/cirrhosis in analyses restricted to liver recipients (Table III).
BL incidence was unrelated to HLA mismatch scores, induction immunosuppression with
monoclonal antibody, or maintenance immunosuppression with cyclosporine, tacrolimus, or
mammalian target of rapamycin (mTOR) inhibitors (Table IV). However, BL incidence was
marginally decreased among those recipients receiving induction immunosuppression with
an interleukin-2 receptor antagonist (IL2RA) (IRR 0.56, 95% CI 0.25–1.08) and
significantly decreased in those receiving polyclonal antibody induction (IRR 0.41, 95% CI
0.17–0.82). BL incidence was marginally decreased among those recipients treated with
azathioprine (IRR 0.69, 95% CI 0.43–1.07) and significantly decreased among those treated
with mycophenolate mofetil (0.64, 95% CI 0.41–0.96) or corticosteroids (0.47, 95% CI
0.29–0.80).
In a multivariate analysis adjusting for age, transplanted organ, and follow-up time, BL
incidence was significantly decreased in female transplant recipients compared to males and
in those who were EBV-seropositive at baseline compared to EBV-seronegative (Table V).
BL risk was significantly lower in blacks compared to whites, but no difference in incidence
was noted when race/ethnicity was categorized as white versus non-white. After adjustment,
receipt of azathioprine and corticosteroids remained significantly associated with decreased
BL incidence, but associations with IL2RA, polyclonal antibodies, and mycophenolate
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mofetil were no longer significant. In analyses restricted to liver recipients, and after
adjustment for variables in the base model, BL incidence remained decreased for non-
cholestatic cirrhosis (IRR 0.46, 95% CI 0.22–0.96) and increased for cholestatic liver
disease/cirrhosis (IRR 3.14, 95% CI 1.51–6.18).
Discussion
Utilizing data from a large registry linkage study of transplant recipients, we show that the
risk of BL in transplant recipients in the U.S. is elevated 23-fold compared to the general
population. The increase might even be higher (410-fold) among HIV-infected transplant
recipients, but this result is based on one case and should be interpreted cautiously. In
multivariate models, BL was positively associated with male sex, transplantation at age <18
years, and receipt of a liver or heart. BL was negatively associated with having a baseline
EBV seropositive status and treatment with azathioprine or corticosteroids.
The higher BL incidence in children and lower incidence in females, independent of EBV,
has been reported in endemic, [19, 20] sporadic, [21] and HIV-related BL. [22] The higher
BL incidence in whites than in blacks has been reported in sporadic BL [21, 23, 24] and
AIDS-related BL. [22] These patterns, common to all subtypes of BL, indicate that age,
gender, and race are markers of intrinsic susceptibility to BL, although the nature of this
susceptibility is unknown. Our finding that BL risk was lower in recipients receiving certain
medications is intriguing. Corticosteroids modulate lymphocyte function and comprise one
component of some therapeutic regimens for BL. [25] We also noted decreased risk of BL in
recipients treated with mTOR inhibitors (IRR= 0.43), but the result was not statistically
significant, perhaps because mTOR inhibitors have only been recently introduced in this
setting.
We found an elevated risk of BL among recipients of heart or liver transplants, which
possibly reflects differences in immunosuppression protocols or immunologic properties
unique to those organs. BL risk was decreased with non-cholestatic cirrhosis and increased
with cholestatic liver disease/cirrhosis as the indications for liver transplant but, because we
examined many medical conditions, these associations may be chance findings.
Our data confirm that EBV is implicated in most (69%) BL cases in transplant recipients.
[11, 13] Our results also indicate that 31% of cases with EBV data were EBV-negative [9].
EBV-negative cases were diagnosed in transplant recipients who were EBV-seropositive at
baseline, suggesting EBV-negativity is not necessarily an indication of lack of EBV
infection at the time of transplantation. Similar results have been described in case reports as
well. [11, 13] EBV positivity in the tumor varied with age. EBV was detected in 90% of
cases of <18 years, but in only 59% of cases diagnosed at or after 18 years. Interestingly, the
high EBV positivity (82%) reported by Picarsic et al. [11] was based on BL cases diagnosed
in recipients aged <18 years. In other settings, EBV positivity is lower in BL adult cases. For
example, EBV positivity is 40–60% in HIV/AIDS-related BL [2], which consists mostly of
adults. Similarly, EBV is detected in at most 20% of cases of sporadic BL, [2, 26] but these
cases also include a substantial proportion of adult cases. Thus, EBV-positive and EBV-
negative BL may be distinct entities, whose distribution might also vary with age. [27] If so,
EBV-positive and EBV-negative BL may originate from distinct progenitor B cells, [28],
carry distinct mutations in host genes,[29–31] and may contribute to multimodal patterns of
BL.[22, 27]
EBV-seronegative transplant recipients experienced a four-fold higher incidence for BL than
those who were EBV-seropositive. This result indicates that the sequential relationship
between EBV infection and onset of immunosuppression influences the risk for BL.
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Nonetheless, baseline EBV serostatus were missing for 66% of recipients, so our inferences
should be interpreted cautiously. The BL latency period was about four years on average,
which contrasts with the steep increase in risk in the first year after transplantation of both
diffuse large B-cell lymphoma (the most common lymphoma in transplant recipients) [32]
and Kaposi sarcoma, [33] although both are also virus-associated malignancies. This longer
latency suggests that progression to BL is due to chronic EBV infection. Alternatively, the
lower incidence of BL in the first few years after transplantation may reflect the intensity of
immunosuppression during that period. We previously noted a paradoxical decline in BL
risk in HIV/AIDS patients with very low CD4 lymphocyte counts, [22] which may be a clue
to the requirement for some functional T cells in BL progression. [22]
The strengths of our study include its large size, representativeness of the U.S. transplant
population, and use of cancer registry linkage for comprehensive and standard identification
of BL cases. Because transplant recipients were classified according to their residence at the
time of transplantation, but overtime, some could have moved away. The impact of this
includes inflating the denominator because these recipients were assumed to still under
follow-up or under estimating the outcomes because BL occurring in those recipients who
moved away would be missed by the cancer registries. However, we have previously
reported that outmigration was quite minimal (approximately 6% at 10 years after
transplantation), [15] thus, it is unlikely to have substantially distorted our estimate of BL
incidence. The lack of central review by expert hematopathologists is a limitation, which
could have introduced misclassification. Incompleteness of data, especially of baseline EBV,
CMV, and HIV serostatus and EBV status of the tumors, are also limitations. In addition,
because we examined many potential BL risk factors, some associations could have been
due to chance.
In conclusion, BL risk is markedly elevated in transplant recipients, and risk is associated
with male sex, young age, baseline EBV status, allograft type, and certain treatments used to
induce therapeutic immunosuppression. BL cases in transplant recipients included both EBV
positive and negative tumors. This suggests the presence of distinct BL entities, which may
differ in etiology.
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Figure 1.
Burkitt lymphoma incidence according to time elapsed since transplant. Bold line shows
actual estimated incidence, light dotted lines indicate upper and lower 95% confidence
intervals of the incidence rate.
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Table I
Characteristics of the U.S. transplant recipient cohort
Characteristic Number of recipients (%)
Sex
 Male 124,246 (61.0)
 Female 79,311 (39.0)
Age at transplant (years)
 0–19 18,149 (8.9)
 20–34 31,202 (15.3)
 35–49 63,831 (31.4)
 50–64 73,423 (36.1)
 65+ 16,952 (8.3)
Race/ethnicity
 White, non-Hispanic 126,051 (61.9)
 Black 34,346 (16.9)
 Hispanic 31,878 (15.7)
 Asian/Pacific Islander 11,282 (5.5)
Transplanted organ
 Kidney 117,660 (57.8)
 Kidney/pancreas or pancreas 9,014 (4.4)
 Liver 44,934 (22.1)
 Heart and/or lung 29,142 (14.3)
 Other or multiple 2,807 (1.4)
Transplant number
 First 185,629 (91.2)
 Second 16,397 (8.1)
 Third or higher 1,531 (0.8)
Calendar year of transplant
 1987–1994 38,818 (19.1)
 1995–1999 52,364 (25.7)
 2000–2004 64,762 (31.8)
 2005–2009 47,613 (23.4)
EBV serostatus at baseline
 Unknown/missing 133,878 (65.8)
 Negative 11,672 (5.7)
 Positive 58,007 (28.5)
HIV status at baseline
 Unknown/missing 127,794 (62.8)
 Negative 75,561 (37.1)
 Positive 202 (0.1)
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Table V
Multivariate associations of Burkitt lymphoma incidence with demographic, clinical, and treatment
characteristics
Characteristic Incidence rate ratios* 95% Confidence intervals
Base model
Gender
 Female 0.45 0.28, 0.71
 Male Ref.
Age at transplant
 0–19 3.49 2.08, 5.68
 20–34 2.36 1.28, 4.10
 35+ Ref.
Race/ethnicity
 White, Non- Hispanic Ref.
 All others ¶ 0.93 0.59, 1.42
Transplanted organ
 Heart 2.39 1.30, 4.31
 Kidney Ref.
 Liver 2.91 1.68, 5.09
 Other 1.01 0.30, 2.59
Baseline EBV serostatus
 Negative Ref.
 Positive 0.34 0.13, 0.93
 Unknown/missing 0.61 0.29, 1.44
Time since transplant
 <2 years 0.12 0.04, 0.27
 2–<3 years 1.73 1.09, 2.70
 3+ years Ref.
Additional variables, adjusted results
Polyclonal antibody
 No Ref.
 Yes 0.64 0.27, 1.32
IL2RA
 No Ref.
 Yes 0.92 0.39, 1.87
Azathioprine
 No Ref.
 Yes 0.56 0.34, 0.89
MMF
 No Ref.
 Yes 1.08 0.67, 1.69
Corticosteroids
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Characteristic Incidence rate ratios* 95% Confidence intervals
 No Ref.
 Yes 0.48 0.29, 0.82
*
The base model includes gender, age at transplant, race, transplanted organ, and EBV status. Estimates for each medication were adjusted for the
variables in the base model, but not for each other.
¶Other includes blacks, Hispanics, and Asians/Pacific Islanders.
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